Stem Cell Transplant Without Mycophenolate Mofetil for Blood Cancer
(OmitMMF Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a pilot study to evaluate the feasibility, safety and potential benefits of removing one immune suppressive drug called mycophenolate mofetil (MMF) from the standard allogenic stem cell transplant treatment protocol.MMF will be omitted from the transplant regimen in 60 eligible patients with hematologic malignancies. Participants will be followed for up to 2 years post standard of care transplant at Cedars-Sinai.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is it safe to omit mycophenolate mofetil in stem cell transplants for blood cancer?
The safety of omitting mycophenolate mofetil in stem cell transplants for blood cancer isn't directly addressed in the available research. However, mycophenolate mofetil itself is known to cause side effects like gastrointestinal issues and increased risk of infections, so omitting it might reduce these risks, but more specific studies are needed to confirm safety in this context.12345
How does omitting the drug mycophenolate mofetil in stem cell transplants for blood cancer differ from other treatments?
This treatment is unique because it omits mycophenolate mofetil, a common immunosuppressive drug used to prevent organ rejection by inhibiting immune cell proliferation. By not using this drug, the treatment may reduce side effects like gastrointestinal issues and infections, which are associated with mycophenolate mofetil.12367
What data supports the effectiveness of omitting the drug mycophenolate mofetil in stem cell transplants for blood cancer?
The research does not provide direct evidence about omitting mycophenolate mofetil in stem cell transplants for blood cancer, but it highlights that mycophenolate mofetil is a strong immunosuppressant with potential side effects like infections, which might be a reason to explore its omission in certain treatments.6891011
Who Is on the Research Team?
Ronald Paquette, MD
Principal Investigator
Cedars-Sinai Medical Center
Are You a Good Fit for This Trial?
This trial is for patients aged 18-75 with blood cancers needing a stem cell transplant and approved by Cedars-Sinai's committee. They must be suitable for a specific chemo and radiation regimen, have not had previous transplants, and have an HLA-matched donor ready to donate stem cells.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Transplantation
Participants undergo allogeneic stem cell transplantation with omission of mycophenolate mofetil
Post-Transplant Monitoring
Participants are monitored for engraftment and acute GVHD up to 100 days post-transplant
Follow-up
Participants are monitored for chronic GVHD, relapse, and overall survival
What Are the Treatments Tested in This Trial?
Interventions
- Omission of the drug mycophenolate mofetil
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ronald Paquette
Lead Sponsor